Peer Review History
Original SubmissionJune 8, 2019 |
---|
PONE-D-19-16309 Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations PLOS ONE Dear MSc Gabriel, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by Feb 21 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Gabriele Fischer, MD Academic Editor PLOS ONE Additional Editor Comments: The authors present a detailed picture of the current status of CPGs for the treatment of depression. Please pay particular attention in addressing the reviewers comments point by point. The raised concern of reviewer 2 that the study should be described as a descriptive study of an existing data set, rather than a systematic review should be emphasized. Further, implications for guideline developers which arise from the authors work should be discussed in more detail. Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating in your Funding Statement: 'FCG NCLS This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001" The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.' a. Please provide an amended statement that declares *all* the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. b. Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf. 3. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 4 in your text; if accepted, production will need this reference to link the reader to the Table. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: N/A ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Major depressive disorder is one of the most prevalent and life-threatening forms of mental illnesses and a major cause of morbidity worldwide. Clinical practice guidelines for depression represent an essential tool to improve patient healthcare by outlining practices recommended based on scientific research. The manuscript entitled “ Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations ” examines the most relevant CPGs for the pharmacological treatment of depression and identifies a matrix of recommendations including agreements and potential disagreements among CPGs. The authors found that all CPGs indicated serotonin selective reuptake inhibitors (SSRIs) as an option for first-line treatment for depression, whereas only three CPGs provided information regarding the evaluation and management of the risk of suicide with pharmacological treatment. In general, the conclusions are supported by the experimental data and this manuscript provides a more comprehensive view of pharmacological approaches to the treatment of depression. Major Currently available antidepressants are effective for most patients, but around 30% are considered treatment resistant (TRD), a condition that is associated with a significant impairment of cognitive function and poor quality of life. The authors found that the level of evidence and strength of recommendations for the combination and augmentation strategies varied among the CPGs. Have the authors found any recommendation in analyzed CPGs for the treatment of depressed patients who did not respond to second-line therapy (TRD patients) ? Reviewer #2: Thank you for the opportunity to review this manuscript. It is well written and provides a clear description the current status of high-quality CPGs for the treatment of depression and provides useful insight into the differences between key guidelines. Methods: This manuscript is based on an data from an existing systematic review (SR) and the authors mention this study as a secondary analysis. I would thus argue that this study is not a systematic review, but rather a descriptive study of an existing dataset (from the previous SR). S1-2 is also thus not needed as these are simply outputs from the previously published SR. In order for this study to qualify as a SR, some form of synthesis should occur, the process of which should be well-described. Thus the method of reporting for this manuscript would be better suited using STROBE than PRISMA. Figure 1 is labelled as a synthesis of CPGs. However, how this synthesis was done is unclear and should be elaborated. At face value, Figure 1 is simply a decision algorithm that provides an vague overview of clinician considerations in patients with suspected depression. Presently, the authors in Tables 1-4 describe the landscape of recommendations across different CPGs grouped by categories, and further elaborate on this in the results section. This is critical realising the authors aim establishing the extent and preventing redundant CPG efforts. Discussion The authors identified useful gaps in CPG recommendations and provide a useful comparative discussion for future CPG developments. Recommendations clearly differed across CPGs, as mentioned, however some CPGs used evidence from standard SR and pair-wise meta-analysis (MA) while others used network MA, which is able to compare multiple treatments. This more appropriate method of evidence synthesis and it's impact on CPG recommendations and as a contributing factor or explanation for the heterogeneity in results should be discussed. Especially as NMA is only recently becoming mainstay in evidence for CPGs Linked to the comments above, the authors, as part of their aim highlight the importance of their work for LMICs guideline developers. However, this is not demonstrated or elaborated on further in the manuscript. Do consider placing the research findings for LMICs as stated in the objectives. The authors mention guideline adaptation, it would be useful to include what these results mean for guideline developers who would use adaptation methods (e.g. those with limited resources, not just in LMICs), what challenges it poses and what further specific research would be needed to create trustworthy CPG considering your results. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
Revision 1 |
Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations PONE-D-19-16309R1 Dear Dr. Gabriel, We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements. Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication. Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. With kind regards, Gabriele Fischer, MD Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: (No Response) Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: (No Response) Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: (No Response) Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: Thank you for clearly addressing reviewer comments. The authors have provided clear rationale for comments to both authors. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: FILIPPO CARACI Reviewer #2: Yes: Michael McCaul |
Formally Accepted |
PONE-D-19-16309R1 Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations Dear Dr. Gabriel: I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. For any other questions or concerns, please email plosone@plos.org. Thank you for submitting your work to PLOS ONE. With kind regards, PLOS ONE Editorial Office Staff on behalf of Professor Gabriele Fischer Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .